Thyroid Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center
|IRB14-0736||A Randomized Phase II Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients with BRAF Mutated Thyroid Carcinoma
|IRB14-0771||An Open-Label Extension(Rollover)Study of Vemurafenib in Patients with BRAFV600 Mutation Positive Malignancies Previously enrolled in an Antecedent Vemurafenib Protocol
|IRB14-0081||Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team